1. Scrip
  2. >>Focus On Asia

China JV Exit To Give Takeda More Focus, Cash

 
• By Ian Haydock

Takeda is selling its majority share in China biopharma joint venture Techpool to focus on its key growth areas in this market and raise cash ahead of the Shire acquisition, in a move that will also boost its former partner’s presence in manufacturing and critical care.

Chinese flag
TAKEDA EXITS TECHPOOL JV IN CHINA • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is divesting its 51.34% share in Chinese biopharmaceutical joint venture Guangdong Techpool Bio-Pharma for around $280m, in a move the Japanese company says will allow it to focus more on key global therapeutic areas and locally unmet needs in the critical Chinese market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia